scholarly journals Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy

2014 ◽  
Vol 150 (11) ◽  
pp. 1209 ◽  
Author(s):  
Frank W. Chen ◽  
Diane Tseng ◽  
Sunil Reddy ◽  
Adil I. Daud ◽  
Susan M. Swetter
Keyword(s):  
Mek Inhibitor ◽  
Inhibitor Therapy ◽  
Melanocytic Nevi

scholarly journals LGG-43. CLINICAL EXPERIENCE OF BRAF AND MEK INHIBITOR THERAPY IN PAEDIATRIC GLIOMA

2018 ◽  
Vol 20 (suppl_2) ◽  
pp. i113-i114
Author(s):  
Patricia O’Hare ◽  
Thalia Loka ◽  
Felice D’Arco ◽  
Sarita Depani ◽  
Anthony Michalski ◽  
...  
Keyword(s):  
Clinical Experience ◽  
Mek Inhibitor ◽  
Inhibitor Therapy

scholarly journals HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma

2019 ◽  
Vol 25 (18) ◽  
pp. 5686-5701 ◽  
Author(s):  
Fernanda Faião-Flores ◽  
Michael F. Emmons ◽  
Michael A. Durante ◽  
Fumi Kinose ◽  
Biswarup Saha ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Mek Inhibitor ◽  
Inhibitor Therapy ◽  
Hdac Inhibition ◽  
In Vivo Efficacy

Dual BRAF/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity

2020 ◽  
Vol 133 (6) ◽  
pp. 1704-1709 ◽  
Author(s):  
Aaron Bernstein ◽  
Oliver D. Mrowczynski ◽  
Amrit Greene ◽  
Sandra Ryan ◽  
Catherine Chung ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Pilocytic Astrocytoma ◽  
Case Series ◽  
Mek Inhibitor ◽  
Pleomorphic Xanthoastrocytoma ◽  
Inhibitor Therapy ◽  
Braf V600e ◽  
Dual Inhibitor ◽  
Cutaneous Toxicity ◽  
Primary Brain Tumors

OBJECTIVEBRAF V600E is a common oncogenic driver in a variety of primary brain tumors. Dual inhibitor therapy using dabrafenib (a selective oral inhibitor of several mutated forms of BRAF kinase) and trametinib (a reversible inhibitor of MEK1 and MEK2) has been used successfully for treatment of metastatic melanoma, anaplastic thyroid cancer, and other tumor types, but has been reported in only a few patients with primary brain tumors and none with pleomorphic xanthoastrocytoma. Here, the authors report on the substantial clinical response and reduction in cutaneous toxicity in a case series of BRAF V600E primary brain cancers treated with dual BRAF/MEK inhibitor therapy.METHODSThe authors treated 4 BRAF V600E patients, each with a different type of primary brain tumor (pilocytic astrocytoma, papillary craniopharyngioma, ganglioglioma, and pleomorphic xanthoastrocytoma) with the combination of dabrafenib and trametinib.RESULTSThe patients with pilocytic astrocytoma, pleomorphic xanthoastrocytoma, and papillary craniopharyngioma experienced near-complete radiographic and complete clinical responses after 8 weeks of therapy. A substantial partial response (by RANO [Response Assessment in Neuro-Oncology] criteria) was observed in the patient with ganglioglioma. The patient with craniopharyngioma developed dramatic, diffuse verrucal keratosis within 2 weeks of starting dabrafenib. This completely resolved within 2 weeks of adding trametinib.CONCLUSIONSDual BRAF/MEK inhibitor therapy represents an exciting treatment option for patients with BRAF V600E primary brain tumors. In addition to greater efficacy than single-agent dabrafenib, this combination has the potential to mitigate cutaneous toxicity, one of the most common and concerning BRAF inhibitor–related adverse events.

Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients

2015 ◽  
Vol 73 (3) ◽  
pp. 491-499.e2 ◽  
Author(s):  
Mark C. Mochel ◽  
Marc R. Hammond ◽  
Dennie T. Frederick ◽  
Maria B. Alora-Palli ◽  
Adriano Piris ◽  
...  
Keyword(s):  
Braf Inhibitor ◽  
Inhibitor Therapy ◽  
Melanocytic Nevi

scholarly journals Bowel perforation associated with robust response to BRAF/MEK inhibitor therapy for BRAF-mutant melanoma: a case report

2015 ◽  
Vol 2 (2) ◽  
pp. 115-120 ◽  
Author(s):  
Samantha L Kass ◽  
Allison F Linden ◽  
Patrick G Jackson ◽  
Pedro A De Brito ◽  
Michael B Atkins
Keyword(s):  
Case Report ◽  
Bowel Perforation ◽  
Mek Inhibitor ◽  
Inhibitor Therapy ◽  
Braf Mutant ◽  
Robust Response
Sign in / Sign up

Export Citation Format

Share Document